Genmab Stock price Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2,046 DKK | +68.12% | +4.14% | +14.24% |
Mar. 18 | Genmab Completes Share Buyback Program | MT |
Mar. 15 | Genmab to Repurchase Up to $511 Million Shares | MT |
Sales 2024 * | 19.61B 2.86B | Sales 2025 * | 23.49B 3.42B | Capitalization | 133B 19.41B |
---|---|---|---|---|---|
Net income 2024 * | 5.18B 754M | Net income 2025 * | 6.88B 1B | EV / Sales 2024 * | 5.29 x |
Net cash position 2024 * | 29.58B 4.31B | Net cash position 2025 * | 34.56B 5.03B | EV / Sales 2025 * | 4.2 x |
P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
19.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.78% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
+1.10% | 106B | |
+9.29% | 103B | |
-2.74% | 21.44B | |
-11.89% | 22.11B | |
-26.59% | 20.99B | |
-6.58% | 17.6B | |
+5.83% | 13.88B | |
+7.46% | 11.75B | |
+28.56% | 11.64B |
- Stock
- Equities
- Stock Genmab A/S
- Stock Genmab - Nasdaq Copenhagen